These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18632312)

  • 1. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome.
    Vine DF; Glimm DR; Proctor SD
    Atheroscler Suppl; 2008 Sep; 9(2):69-76. PubMed ID: 18632312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels.
    Mangat R; Warnakula S; Wang Y; Russell JC; Uwiera R; Vine DF; Proctor SD
    Atheroscler Suppl; 2010 Jun; 11(1):17-24. PubMed ID: 20471328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome.
    Mangat R; Su J; Scott PG; Russell JC; Vine DF; Proctor SD
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):477-81. PubMed ID: 17511632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Insights into the Regulation of Chylomicron Production.
    Dash S; Xiao C; Morgantini C; Lewis GF
    Annu Rev Nutr; 2015; 35():265-94. PubMed ID: 25974693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin treatment upregulates intestinal lipid secretion pathways in a rodent model of the metabolic syndrome.
    Borthwick F; Mangat R; Warnakula S; Jacome-Sosa M; Vine DF; Proctor SD
    Atherosclerosis; 2014 Jan; 232(1):141-8. PubMed ID: 24401228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome.
    Vine DF; Takechi R; Russell JC; Proctor SD
    Atherosclerosis; 2007 Feb; 190(2):282-90. PubMed ID: 16624317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into how the intestine can regulate lipid homeostasis and impact vascular disease: frontiers for new pharmaceutical therapies to lower cardiovascular disease risk.
    Warnakula S; Hsieh J; Adeli K; Hussain MM; Tso P; Proctor SD
    Can J Cardiol; 2011; 27(2):183-91. PubMed ID: 21459267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity.
    Hsieh J; Hayashi AA; Webb J; Adeli K
    Atheroscler Suppl; 2008 Sep; 9(2):7-13. PubMed ID: 18653387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.
    Hsieh J; Longuet C; Maida A; Bahrami J; Xu E; Baker CL; Brubaker PL; Drucker DJ; Adeli K
    Gastroenterology; 2009 Sep; 137(3):997-1005, 1005.e1-4. PubMed ID: 19482026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hypertriglyceridemia promotes intestinal lymphatic lipid and drug transport: a positive feedback mechanism in lipid and drug absorption.
    Trevaskis NL; Charman WN; Porter CJ
    Mol Pharm; 2011 Aug; 8(4):1132-9. PubMed ID: 21604764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic dietary n-3 PUFA intervention improves dyslipidaemia and subsequent cardiovascular complications in the JCR:LA- cp rat model of the metabolic syndrome.
    Lu J; Borthwick F; Hassanali Z; Wang Y; Mangat R; Ruth M; Shi D; Jaeschke A; Russell JC; Field CJ; Proctor SD; Vine DF
    Br J Nutr; 2011 Jun; 105(11):1572-82. PubMed ID: 21276281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ApoA-1 infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance.
    Borthwick F; Warnakula S; Mangat R; Uwiera RR; Russell JC; Kelly SE; Lee CY; Hryshko L; Mamo JC; Rye KA; Lopaschuk GD; Proctor SD
    Atherosclerosis; 2012 Jun; 222(2):402-8. PubMed ID: 22483015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and post-prandial lipid metabolism. Feast or famine?
    Martins IJ; Redgrave TG
    J Nutr Biochem; 2004 Mar; 15(3):130-41. PubMed ID: 15023394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of chylomicron production in humans.
    Xiao C; Lewis GF
    Biochim Biophys Acta; 2012 May; 1821(5):736-46. PubMed ID: 22001638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary carbohydrates and intestinal lipoprotein production.
    Morgantini C; Xiao C; Dash S; Lewis GF
    Curr Opin Clin Nutr Metab Care; 2014 Jul; 17(4):355-9. PubMed ID: 24763064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macronutrient intake and modulation on chylomicron production and clearance.
    Lairon D
    Atheroscler Suppl; 2008 Sep; 9(2):45-8. PubMed ID: 18595783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal lipid absorption and lipoprotein formation.
    Hussain MM
    Curr Opin Lipidol; 2014 Jun; 25(3):200-6. PubMed ID: 24751933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From fatty-acid sensing to chylomicron synthesis: role of intestinal lipid-binding proteins.
    Buttet M; Traynard V; Tran TT; Besnard P; Poirier H; Niot I
    Biochimie; 2014 Jan; 96():37-47. PubMed ID: 23958439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triglyceride-rich lipoproteins and cytosolic lipid droplets in enterocytes: key players in intestinal physiology and metabolic disorders.
    Demignot S; Beilstein F; Morel E
    Biochimie; 2014 Jan; 96():48-55. PubMed ID: 23871915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis.
    Huff MW
    Can J Clin Pharmacol; 2003; 10 Suppl A():26A-32A. PubMed ID: 14571303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.